Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
Jua Choi,Olivier Aubert,Ashley Vo,Alexandre Loupy,Mark Haas,Dechu Puliyanda,Irene Kim,Sabrina Louie,Alexis Kang,Alice Peng,Joe Kahwaji,Nancy L. Reinsmoen,Mieko Toyoda,Stanley C. Jordan +13 more
Reads0
Chats0
TLDR
Tocilizumab provides good long‐term outcomes for patients with cAMR and TG, especially compared with historical published treatments, and inhibition of the IL‐6–IL‐6 receptor pathway may represent a novel approach to stabilize allograft function and extend patient lives.About:
This article is published in American Journal of Transplantation.The article was published on 2017-09-01 and is currently open access. It has received 266 citations till now. The article focuses on the topics: Transplant glomerulopathy & Tocilizumab.read more
Citations
More filters
Journal ArticleDOI
COVID-19 and the Heart.
TL;DR: What is known about the pathophysiology of COVID-19, its cardiovascular manifestations, and emerging therapeutic prospects is reviewed.
Journal ArticleDOI
Antibody-Mediated Rejection of Solid-Organ Allografts.
TL;DR: This review focuses on current standards for management of antibody-mediated rejection in solid-organ transplant recipients and emphasizes the importance of informed consent for the use of antibodies for organ transplantation.
Journal ArticleDOI
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Farsad Eskandary,Heinz Regele,Lukas Baumann,Gregor Bond,Nicolas Kozakowski,Markus Wahrmann,Luis G. Hidalgo,Helmuth Haslacher,Christopher C. Kaltenecker,Marie-Bernadette Aretin,Rainer Oberbauer,Martin Posch,Anton Staudenherz,Ammon Handisurya,Jeff Reeve,Philip F. Halloran,Georg A. Böhmig +16 more
TL;DR: This trial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity, and reinforces the need for systematic trials to dissect the efficiency and safety of new treatments for late ABMR.
Journal ArticleDOI
Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.
Carrie A. Schinstock,Roslyn B. Mannon,Klemens Budde,Anita S. Chong,Mark Haas,Stuart J. Knechtle,Carmen Lefaucheur,Robert A. Montgomery,Peter Nickerson,Stefan G. Tullius,Curie Ahn,Medhat Askar,Marta Crespo,Steven J. Chadban,Sandy Feng,Stanley C. Jordan,Kwan Man,Michael Mengel,Randall E. Morris,Inish O’Doherty,Binnaz Handan Ozdemir,Daniel Serón,Anat R. Tambur,Kazunari Tanabe,Jean Luc Taupin,Jean Luc Taupin,Philip J. O'Connell +26 more
TL;DR: A meeting of international experts to develop a consensus as to what is appropriate treatment for active and chronic active antibody-mediated rejection (AMR) was held, with no conclusive evidence to support any specific therapy.
Journal ArticleDOI
Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies
Nicole Valenzuela,Elaine F. Reed +1 more
TL;DR: The clinical and histological manifestations of AMR are described, and the immunopathological mechanisms contributing to antibody-mediated allograft injury as well as current and emerging therapies are discussed.
References
More filters
Journal ArticleDOI
IL-6 in Inflammation, Immunity, and Disease
TL;DR: The mechanism for the continual synthesis of IL-6 needs to be elucidated to facilitate the development of more specific therapeutic approaches and analysis of the pathogenesis of specific diseases.
Journal ArticleDOI
IL-6 as a keystone cytokine in health and disease
TL;DR: The effect of IL-6 on innate and adaptive immunity and the possible advantages of various antagonists ofIL-6 are discussed and how the immunobiology of IL -6 may inform clinical decisions is considered.
Journal ArticleDOI
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
Joana Sellarés,D. G. de Freitas,Michael Mengel,Jeff Reeve,Gunilla Einecke,Banu Sis,Luis G. Hidalgo,Konrad S. Famulski,Arthur J. Matas,Philip F. Halloran +9 more
TL;DR: This prospective cohort indicates that many actual failures after indication biopsies manifest phenotypic features of antibody‐mediated or mixed rejection and also underscores the major role of nonadherence.
Journal ArticleDOI
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions
Mark Haas,Banu Sis,Lorraine C. Racusen,Kim Solez,Denis Glotz,Robert B. Colvin,Maria Castro,D. S. R. David,Elias David-Neto,Serena M. Bagnasco,Linda C. Cendales,Lynn D. Cornell,Anthony J. Demetris,Cinthia B. Drachenberg,Carol Farver,Alton B. Farris,Ian W. Gibson,Edward S. Kraus,Helen Liapis,Alexandre Loupy,Volker Nickeleit,Parmjeet Randhawa,E. R. Rodriguez,David N. Rush,Rex Neal Smith,Carmela D. Tan,William D. Wallace,Michael Mengel +27 more
TL;DR: The 12th Banff Conference on Allograft Pathology was held in Comandatuba, Brazil, from August 19-23, 2013, and was preceded by a 2-day Latin American Symposium on Transplant Immunobiology and Immunopathology.
Journal ArticleDOI
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN').
Kim Solez,Robert B. Colvin,Lorraine C. Racusen,Banu Sis,Philip F. Halloran,Patricia E. Birk,Patricia Campbell,Marilia Cascalho,A. B. Collins,Anthony J. Demetris,Cinthia B. Drachenberg,Ian W. Gibson,Paul C. Grimm,Mark Haas,Evelyne Lerut,Helen Liapis,Roslyn B. Mannon,P. B. Marcus,Michael Mengel,Michael J. Mihatsch,Brian J. Nankivell,Volker Nickeleit,John C. Papadimitriou,Jeffrey L. Platt,Parmjeet Randhawa,Ian Roberts,L. Salinas-Madriga,Daniel R. Salomon,Daniel Serón,M. Sheaff,Jan J. Weening +30 more
TL;DR: The 8th Banff Conference on Allograft Pathology was held in Edmonton, Canada, 15–21 July 2005, and major outcomes included the elimination of the non‐specific term ‘chronic allograft nephropathy’ (CAN) and the recognition of the entity of chronic antibody‐mediated rejection.
Related Papers (5)
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions
Mark Haas,Banu Sis,Lorraine C. Racusen,Kim Solez,Denis Glotz,Robert B. Colvin,Maria Castro,D. S. R. David,Elias David-Neto,Serena M. Bagnasco,Linda C. Cendales,Lynn D. Cornell,Anthony J. Demetris,Cinthia B. Drachenberg,Carol Farver,Alton B. Farris,Ian W. Gibson,Edward S. Kraus,Helen Liapis,Alexandre Loupy,Volker Nickeleit,Parmjeet Randhawa,E. R. Rodriguez,David N. Rush,Rex Neal Smith,Carmela D. Tan,William D. Wallace,Michael Mengel +27 more
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
Mark Haas,Alexandre Loupy,Carmen Lefaucheur,Candice Roufosse,Denis Glotz,Daniel Serón,Brian J. Nankivell,Philip F. Halloran,Robert B. Colvin,Enver Akalin,Nada Alachkar,Serena M. Bagnasco,Yassine Bouatou,Yassine Bouatou,Jan U. Becker,Lynn D. Cornell,J.-P. Duong Van Huyen,Ian W. Gibson,Edward S. Kraus,Roslyn B. Mannon,Maarten Naesens,Volker Nickeleit,Peter Nickerson,Dorry L. Segev,Harsharan K. Singh,Mark D. Stegall,P. Randhawa,Lorraine C. Racusen,Kim Solez,Michael Mengel +29 more